Rebates, Pricing Pressure Weigh On J&J's Q1 Pharma Sales

Johnson & Johnson had to offer steeper discounts in certain therapeutic categories like cardiovascular and metabolic disease, impacting first quarter sales. So far, the impact of a new biosimilar in the US has had minimal impact on Remicade.